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Venom proteomics and antivenom 
neutralization for the Chinese 
eastern Russell’s viper, Daboia 
siamensis from Guangxi and Taiwan
Kae Yi Tan1, Nget Hong Tan1 & Choo Hock Tan2
The eastern Russell’s viper (Daboia siamensis) causes primarily hemotoxic envenomation. Applying 
shotgun proteomic approach, the present study unveiled the protein complexity and geographical 
variation of eastern D. siamensis venoms originated from Guangxi and Taiwan. The snake venoms 
from the two geographical locales shared comparable expression of major proteins notwithstanding 
variability in their toxin proteoforms. More than 90% of total venom proteins belong to the toxin 
families of Kunitz-type serine protease inhibitor, phospholipase A2, C-type lectin/lectin-like protein, 
serine protease and metalloproteinase. Daboia siamensis Monovalent Antivenom produced in 
Taiwan (DsMAV-Taiwan) was immunoreactive toward the Guangxi D. siamensis venom, and 
effectively neutralized the venom lethality at a potency of 1.41 mg venom per ml antivenom. This 
was corroborated by the antivenom effective neutralization against the venom procoagulant 
(ED = 0.044 ± 0.002 µl, 2.03 ± 0.12 mg/ml) and hemorrhagic (ED50 = 0.871 ± 0.159 µl, 7.85 ± 3.70 mg/
ml) effects. The hetero-specific Chinese pit viper antivenoms i.e. Deinagkistrodon acutus Monovalent 
Antivenom and Gloydius brevicaudus Monovalent Antivenom showed negligible immunoreactivity 
and poor neutralization against the Guangxi D. siamensis venom. The findings suggest the need for 
improving treatment of D. siamensis envenomation in the region through the production and the use of 
appropriate antivenom.
Daboia is a genus of the Viperinae subfamily (family: Viperidae), comprising a group of vipers commonly known 
as Russell’s viper native to the Old World1. The Russell’s viper was previously recognised as monotypic Daboia rus-
selii or Vipera russelii with at least seven subspecies following an extremely disjunct distribution over a large area 
of Asian countries, from Pakistan, India, Sri Lanka, Myanmar, Thailand, Cambodia, Java and islands of Lesser 
Sunda in Indonesia, to South China (Guangdong and Guangxi) and the insular Taiwan. Based on mitochondrial 
DNA and multivariate morphological analyses, Thorpe et al.2 suggested that the Russell’s viper complex diverged 
approximately 7–11 mybp (million years before present) into the eastern and the western clades, separated by a 
narrow range of mountains in northwest Burma to the north of the Bay of Bengal. This led to the revision of the 
entire Russell’s viper complex systematics, sinking several subspecies into synonyms that followed biogeographi-
cal distribution while elevating Daboia russelii russelii and Daboia russelii siamensis to their respective full species 
status. Currently, Daboia russelii represents the Western Russell’s viper that is indigenous to South Asia, while the 
Eastern Russell’s viper (Daboia siamensis) distributes in Southeast and East Asia, comprising the former subspe-
cies limitis, sublimitis and formosensis2–4.
The differences between the two species of Russell’s vipers are, in fact, not limited to their morphology and 
molecular phylogenies. Differences in the envenoming effects of the Russell’s viper have been reported, attributa-
ble to the plasticity of snake venom as an adaptive polygenic trait of venomous snakes5,6. The observed variations 
of the envenomation, however, did not conform to the phylogenetics and systematics7–9. This implies that within 
each Daboia species, venom variation is common and the investigation of the venom composition should be 
directed toward detailed venom characterization based on the distinctive species and the geographical locale 
from where the venom originates. Indeed, the pathogenesis of snakebite envenomation correlates with venom 
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composition, and it is well established that even within the same species of D. russelii, the venom composition 
can vary across different locales10–13. With the recent advent of proteomic technologies, the compositions of D. 
russelii venoms of different regions in South Asia (Pakistan, western India, southern India and Sri Lanka) have 
been unravelled to great details, improving our understanding of the clinicopathological correlation and effective-
ness of antivenom treatment12–16. For instance, the Sri Lankan D. russelii venom contain substantial neurotoxic 
phospholipases A2 that correlated with the neurotoxic activity of the venom in animal experiment and clini-
cal envenomation8,15. In contrast, the proteomic characterization of D. siamensis venom received less attention 
although envenoming by this species remains prevalent in many parts of the world including the southern main-
land of China17–20, insular Taiwan21, Indonesia22, Thailand23,24 and Myanmar25–28. Several toxins had been isolated 
previously from D. siamensis venom, including Kunitz-type serine protease inhibitors29,30, phospholipases A231, 
snaclecs32, snake venom serine proteases33 and snake venom metalloproteinases34–36. The venom proteome of 
the Myanmese D. siamensis has also been reported37; however, the knowledge on the quantitative details and 
geographical variability of D. siamensis venom proteins from different locales remain unclear. In particular, the 
venom proteomes of D. siamensis of the far eastern lineage, namely those from the mainland of China and insular 
Taiwan may be geographically varied. The knowledge is much needed for comparative study of Russell’s viper 
venoms to better understand the clinicopathological correlation of envenomation and the efficacy of antivenom 
treatment.
D. siamensis envenomation can cause painful local effect with systemic bleeding disorders, typically mani-
fested as venom-induced consumptive coagulopathy38 which may be accompanied with complications such as 
hypopituitarism and renal failure25,39–41. In particular, acute or chronic hypopituitarism is associated more com-
monly with clinical cases from Myanmar39,42, although this effect has also been noted recently in a few cases from 
Sri Lanka (D. russelii envenomation)9,26. The envenomation by D. siamensis, however, unlike envenoming by the 
Sri Lankan D. russelii, rarely produces neuromuscular paralysis in the envenomed patients21. D. siamensis is 
locally known as “round-spot viper” ( ) in the China mainland and “chain snake/viper” ( ) in Taiwan 
Island. The incidence of snakebite and antivenom treatment of D. siamensis envenomation, however, differ across 
the Strait. In general, D. siamensis envenomation affects the agricultural populations and people engaging in field 
activities; nonetheless, in areas where venomous snakes are bred or sought for local delicacy and health supple-
ment, the snake farmers, traders and handlers including cooks also bear the risk of envenomation. Literature on 
Chinese D. siamensis envenomation is, however, scarce and less accessible as most clinical reports were lodged in 
the Chinese depository17–20. Where antivenom treatment is concerned in the two geographical areas, the specific 
antivenom indicated for D. siamensis envenoming, herewith known as D. siamensis Monovalent Antivenom 
(DsMAV-Taiwan) is only available in Taiwan, despite the fact that D. siamensis is also distributed across the south-
ern part of the mainland of China. The unavailability of D. siamensis antivenom led to the non-specific use of 
hetero-specific “viperid” Chinese antivenoms i.e. the Gloydius brevicaudus (short-tailed Chinese mamushi) 
Monovalent Antivenom (GbMAV) and Deinagkistrodon acutus (sharp-nosed pit viper) Monovalent Antivenom 
(DaMAV), either singly or combined to treat D. siamensis envenoming clinically. Failure of treatment including 
death outcome has been reported anecdotally following the administration of these inappropriate antivenoms.
Worldwide, there are at least two major antivenom manufacturers that produce specific antivenom against the 
eastern Russell’s viper: (1) In Taiwan, the Centers for Disease Control (CDC) produces the Taiwanese D. siamensis 
Monovalent Antivenom (DsMAV-Taiwan); (2) In Thailand, the Queen Saovabha Memorial Institute (QSMI) 
produces the Thai D. siamensis Monovalent Antivenom (DsMAV-Thai) and Hemato Polyvalent Antivenom (a 
polyvalent antivenom raised against three Viperidae snakes of Thai origin). This study aimed to investigate and 
compare the venom proteomes of D. siamensis from Guangxi and Taiwan in correlation with the toxicity of the 
venoms. The immunoreactivity of different antivenoms and neutralization of the venoms were also investigated.
Result
SDS-PAGE and proteomes of Daboia siamensis venoms. The venoms of D. siamensis from 
Guangxi (Ds-Guangxi) and Taiwan (Ds-Taiwan) were separated by 15% SDS-PAGE under reducing conditions. 
Electrophoretic bands corresponding to proteins with molecular weights ranging from below 10 to 140 kDa were 
observed as shown in Fig. 1(a). The proteins in both the venoms shared a similar pattern of band distribution, 
while differences in the gel band density were noted in the proteins of 13–15 kDa (more intense in Ds-Taiwan) 
and 70–140 kDa (more intense in Ds-Guangxi). Nano-ESI-LCMS/MS analyses revealed that there were a total of 
47 proteins constituting 12 protein families in the Ds-Guangxi venom and 28 proteins constituting 9 protein fam-
ilies in the Ds-Taiwan venom (Table 1). The majority of venom protein families were shared between Ds-Guangxi 
and Ds-Taiwan venoms whereas L-amino acid oxidase (LAAO), 5′-nucleotidase (5′NUC) and cysteine-rich secre-
tory protein (CRiSP) were only detected in the Ds-Guangxi venom.
Kunitz-type serine protease inhibitors (KSPI) and phospholipases A2 (PLA2) are the two most abundantly 
expressed toxin families in the venoms. These two protein families together constitute 45–50% of the total venom 
proteins (Fig. 1). The toxin proteoforms detected, nonetheless, varied between the two venoms (Table 1). A total 
of 5 KSPI forms were identified in the Ds-Taiwan venom, while in the Ds-Guangxi venom there were only 3 
KSPI forms. The proteoforms of PLA2 identified also varied between the two: in the Ds-Guangxi venom, the 6 
PLA2 forms detected were distinct from 2 PLA2 proteoforms (RV-4 and RV-7) present in the Ds-Taiwan venom. 
Snaclec (snake venom C-type lectin/lectin-like protein) made up about 17% of protein bulk in both venoms. 
Snake venom serine proteases (SVSP) were slightly more abundant in the Ds-Taiwan venom (17.51%) com-
pared with the Ds-Guangxi venom (13.61%), while the Ds-Guangxi venom showed a higher abundance of snake 
venom metalloproteinases (SVMP, 8.92%) than that of the Ds-Taiwan venom (5.86%). Besides, both venoms 
contained comparable abundances of 4 minor protein families (svVEGF, ~5%; svNGF, ~2%; PDE, ~0.3%; putative 
toxin aminopeptidase, ~0.3%) (Table 1). The peptide sequences and data of mass spectrometry are available in 
Supplementary Information files S2A and S2B.
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Antivenom protein concentrations. Table 2 shows the protein concentrations of four antivenoms deter-
mined using the bicinchoninic acid (BCA) protein assay kit, with bovine serum albumin as the standard for 
protein calibration.
Immunoreactivity of antivenoms to D. siamensis venoms. The four antivenoms (DsMAV-Taiwan, 
DsMAV-Thai, DaMAV and GbMAV) and an additional combination of DaMAV and GbMAV in a ratio of 1:1 
were tested for their immunological binding activity toward Ds-Guangxi and Ds-Taiwan venoms (Fig. 2). The 
highest immunoreactivity (reflecting antigen binding activity) was observed in the reaction of DsMAV-Taiwan 
with Ds-Taiwan venom (Fig. 2). The Ds-Guangxi venom showed a lower immunoreactivity (approximately 
50% lower) when reacting with the homologous antivenom from Taiwan. Both venoms also showed immuno-
reactivity for DsMAV-Thai but the relative magnitude of reactivity was apparently lower, found in the range of 
15% (Ds-Guangxi) to 30% (Ds-Taiwan). The heterologous antivenoms (DaMAV, GbMAV and a combination 
of DaMAV:GbMAV in a ratio of 1:1) were generally low in immunoreactivity (<10%) to both Ds-Guangxi and 
Ds-Taiwan venoms.
Procoagulant activity of D. siamensis venoms and antivenom neutralization. Both D. siamensis 
venoms exhibited potent procoagulant effect with minimal coagulation dose (MCD) of 0.23 ± 0.06 µg/ml and 
0.15 ± 0.04 µg/ml for Ds-Guangxi and Ds-Taiwan venoms, respectively (Table 3). DsMAV-Taiwan neutralized 
the procoagulant effect of Ds-Guangxi and Ds-Taiwan venoms in a dose-dependent manner (Fig. 3A), and the 
efficacy values of neutralization (defined as ED, effective dose) were comparable for both venoms (ED = ~1.4 to 
2.0 mg venom neutralized per millilitre of antivenom, Table 3). The neutralization by GbMAV was extremely 
poor, at least 30-fold less effective compared with DsMAV-Taiwan. On the other hand, DaMAV was totally inef-
fective in neutralizing the procoagulant effect of Ds-Guangxi and Ds-Taiwan venoms. For comparison, the effec-
tive doses of the antivenoms were normalized by the respective protein concentrations (Table 3). The normalized 
effective dose (n-ED) for procoagulant effect of DsMAV-Taiwan (in mg/g, milligram of venom neutralized per 
gram of antivenom protein) was at least 250-fold higher than those of GbMAV and DaMAV.
Hemorrhagic activity of Daboia siamensis venoms and antivenom neutralization. The Ds-Guangxi 
venom showed a lower minimal hemorrhagic dose (MHD) of 3.42 ± 0.12 µg/mouse compared with the Ds-Taiwan 
venom (MHD = 8.21 ± 0.31 µg/mouse). DsMAV-Taiwan neutralized the hemorrhagic effect of the venoms 
dose-dependently (Fig. 3B), but the neutralization was much more effective against the hemorrhagic effect of 
Ds-Taiwan venom than that of Ds-Guangxi venom based on the normalized median effective doses (n-ED50) 
(Table 4). In comparison with DsMAV-Taiwan, GbMAV and DaMAV were extremely weak in neutralizing the 
hemorrhagic effect induced by the D. siamensis venoms. DsMAV-Taiwan was at least 70–300 folds more effective 
in neutralizing the hemorrhagic effect.
Lethality of D. siamensis venoms and in vivo neutralization in mice. When administrated intra-
venously, Ds-Guangxi and Ds-Taiwan venoms had median lethal doses (LD50) of 0.18 µg/g and 0.09 µg/g, 
Figure 1. SDS-PAGE and proteomes of Daboia siamensis venoms. (a) D. siamensis and lyophilized venoms 
(top) and protein separation of Ds-Guangxi and Ds-Taiwan venoms on 15% SDS-PAGE under reducing 
conditions (bottom). (b) Venom proteome of Ds-Guangxi. (c) Venom proteome of Ds-Taiwan. The number 
of proteoforms of each protein family is in parentheses. Abbreviations: Ds-Guangxi: D. siamensis of Guangxi 
(mainland); Ds-Taiwan, D. siamensis of Taiwan (island); KSPI, Kunitz-type serine protease inhibitor; PLA2, 
phospholipase A2; Snaclec, snake venom C-type lectin/lectin-like protein; SVSP, snake venom serine protease; 
SVMP, snake venom metalloproteinase; LAAO, L-amino acid oxidase; svVEGF, snake venom vascular 
endothelial growth factor; svNGF, snake venom nerve growth factor; 5′NUC, 5′-nucleotidase; CRiSP, cysteine-
rich secretory protein; PDE, phosphodiesterase. Note: SDS-PAGE of Ds-Guangxi and Ds-Taiwan venoms 
were cropped from the same gel for display purpose. The full-length gel is provided in the Supplementary 
Information File S1.
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Protein Name Database Accession Species
D. siamensis (Guangxi) D. siamensis (Taiwan)
% Proteoform % Proteoform
Kunitz-type serine protease inhibitor (KSPI) 23.17 3 28.21 5
Kunitz-type serine protease inhibitor C1 A8Y7N4 D. siamensis — — 12.18 1
Kunitz-type serine protease inhibitor C4 A8Y7N7 D. siamensis — — 3.51 2
Kunitz-type serine protease inhibitor B4 A8Y7P4 D. siamensis 6.53 1 3.43 3
Kunitz-type serine protease inhibitor B5 A8Y7P5 D. siamensis 4.91 2 — —
Kunitz-type serine protease inhibitor B6 A8Y7P6 D. siamensis — — 1.77 4
Kunitz-type serine protease inhibitor 2 P00990 D. siamensis 11.72 3 7.31 5
Phospholipase A2 (PLA2) 22.18 6 24.47 2
Acidic phospholipase A2 RV-7 P31100 D. siamensis — — 10.87 1
Basic phospholipase A2 RV-4 Q02471 D. siamensis — — 13.61 2
Acidic phospholipase A2 daboiatoxin A chain Q7T2R1 D. siamensis 5.30 1 — —
Acidic phospholipase A2 daboiatoxin B chain Q7T3T5 D. siamensis 4.29 2 — —
Basic phospholipase A2 DsM-b1 A8CG82 D. siamensis 2.38 3 — —
Acidic phospholipase A2 DsM-a2 A8CG78 D. siamensis 4.21 4 — —
Basic phospholipase A2 Drk-b1 A8CG89 D. russelii 5.05 5 — —
phospholipase A2-I Q7ZZQ1 D. siamensis 0.96 6 — —
Snake venom C-type lectin/lectin-like protein (snaclec) 16.89 10 16.52 6
Snaclec dabocetin subunit alpha Q38L02 D. siamensis 1.35 1 — —
Snaclec A12 B4XSY7 M. lebetina 0.64 2 — —
C-type lectin A12 Unigene30367_DrSL* D. russelii 0.28 3 — —
Snaclec 7 Q4PRC6 D. siamensis 2.93 4 — —
Snaclec 5 Q4PRC8 D. siamensis 1.02 5 — —
Snaclec 4 Q4PRC9 D. siamensis 2.01 6 1.43 1
Snaclec 3 Q4PRD0 D. siamensis 1.48 7 1.03 2
P31 alpha subunit K9JBU9 D. siamensis 0.48 8 — —
P68 alpha subunit K9JBV0 D. siamensis 5.86 9 5.95 3
Snaclec coagulation factor X-activating enzyme light chain 1 Q4PRD1 D. siamensis — — 4.77 4
Snaclec coagulation factor X-activating enzyme light chain 2 Q4PRD2 D. siamensis 0.84 10 2.07 5
Factor X activator light chain 2 K9JDJ1 D. siamensis — — 1.28 6
Snake venom serine protease (SVSP) 13.61 9 17.51 6
Alpha-fibrinogenase-like E5L0E3 D. siamensis 0.77 1 1.01 1
Beta-fibrinogenase E0Y419 M. lebetina 1.57 2 0.74 2
Beta-fibrinogenase-like E5L0E4 D. siamensis 2.50 3 — —
serine beta-fibrinogenase-like protein CL2958.contig11_DrSL* D. russelii 0.71 4 2.38 3
Factor V activator RVV-V gamma P18965 D. siamensis 2.79 5 8.11 4
Vipera russelli proteinase RVV-V homolog 2 P86531 D. russelii 0.59 6 — —
RVV-V gamma-like protein CL31.contig2_Nn* N. naja 1.14 7 2.19 5
Venom serine proteinase-like protein 2 Q9PT40 M. lebetina 0.30 8 — —
Serine protease VLSP-1 CL2958.contig6_DrSL* D. russelii 3.25 9 3.07 6
Snake venom metalloproteinase (SVMP) 8.92 6 5.86 4
Zinc metalloproteinase-disintegrin-like daborhagin-K B8K1W0 D. russelii 4.44 1 — —
Zinc metalloproteinase-disintegrin-like VLAIP-A Q4VM08 M. lebetina 0.36 2 1.34 1
Zinc metalloproteinase-disintegrin VLAIP-A CL3662.contig2_DrSL* D. russelii 1.02 3 1.62 2
Zinc metalloproteinase-disintegrin VLAIP-A Unigene31385_Nn* N. naja 0.83 4 0.44 3
Coagulation factor X-activating enzyme heavy chain Q7LZ61 D. siamensis — — 2.45 4
factor X activator heavy chain K9JAW0 D. russelii 1.03 5 — —
factor X activator heavy chain Unigene32626_DrSL* D. russelii 1.25 6 — —
L-amino acid oxidase (LAAO) 5.95 4 — —
L-amino-acid oxidase G8XQX1 D. russelii 1.29 1 — —
L-amino-acid oxidase P0C2D7 V. berus berus 1.84 2 — —
L-amino-acid oxidase P81382 C. rhodostoma 0.35 3 — —
L-amino-acid oxidase Q4F867 D. siamensis 2.47 4 — —
Snake venom vascular endothelial growth factor (svVEGF) 4.79 1 4.84 1
Snake venom vascular endothelial growth factor toxin VR-1 P0DL42 D. siamensis 4.79 1 4.84 1
Snake venom nerve growth factor (svNGF) 2.11 1 2.13 1
Continued
www.nature.com/scientificreports/
5SCienTiFiC REPORTS |  (2018) 8:8545  | DOI:10.1038/s41598-018-25955-y
respectively (Table 5). DsMAV-Taiwan showed dose-dependent neutralization effects against the lethality of the 
venoms (constituting 5 LD50) (Fig. 3C). As the two venoms were different in their LD50 and the total amount 
of venom injected, the lethality neutralization was expressed in terms of neutralization potency (P) (Table 5). 
The neutralization of DsMAV-Taiwan was slightly more potent on Ds-Taiwan venom (P = 1.62 mg/ml, or 
n-P = 83.9 mg/g) than on Ds-Guangxi venom (P = 1.41 mg/ml, or normalized potency, n-P = 73.1 mg/g). On the 
other hand, GbMAV had a much lower potency of cross-neutralization against the venom lethality (P = 0.17 mg/ml 
or n-P = 1.0 mg/g), at least 70-fold lesser when comparing with the n-P values of DsMAV-Taiwan. DaMAV was 
totally ineffective to cross-neutralize the venom lethality at the maximal dose of antivenom (200 µl) administered 
intravenously into the mice.
Discussion
Thorpe et al.2 suggested that the eastern Russell’s viper underwent an almost simultaneous rapid divergence 2–3 
mybp. The Myanmese or Cambodian specimen is basal in the phylogenetic tree, while the Javan branch is sister 
to the geographically distant Chinese and Taiwanese branches2. This was likely to be at a time of mainland range 
expansion that enabled rapid overland colonization of the snake into the Taiwan once physically joined to the 
mainland of China over the Pleistocene43. Nonetheless, the clinical manifestations of snakebite envenoming often 
show marked geographical variations that are broadly unrelated to the phylogeny, and this phenomenon has been 
elucidated by venom proteomic and transcriptomic studies of a number of snake species6,10,11,14,44. Hence, the 
observed incongruence between the envenoming effects and the primary phylogenetic division of the Russell’s 
viper complex does not allow the prediction of Russell’s viper envenoming effects and antivenom responses in 
areas where these have not been studied directly2,10,12,14. In this context, D. siamensis venoms from the southern 
China and Taiwan were reported to cause hemotoxic envenomation19–21; however, knowledge on the venom com-
position was largely limited to isolated toxins of specimens from either the insular Taiwan31,32,34,45 or mainland 
China46–48. Using a comparative approach, this present work successfully unveiled the proteomes and toxic prop-
erties of the venom sourced from two locales (Guangxi and Taiwan). The findings revealed a greater number of 
protein families in the proteomes of the two D. siamensis venoms than that of Myanmese D. siamensis reported 
previously where only six protein families were identified (i.e. phospholipase A2, PLA2; C-type lectin/lectin-like 
protein, snaclecs; L-amino acid oxidase. LAAO; snake venom serine protease, SVSP; snake venom metallopro-
teinase, SVMP and snake venom vascular endothelial growth factor; svVEGF)37. The discrepancy observed could 
be probably due to different techniques used, as the current approach (integrating whole venom in-solution shot-
gun proteomics with recent database mining) might be a more sensitive venomic tool for studying the complexity 
Protein Name Database Accession Species
D. siamensis (Guangxi) D. siamensis (Taiwan)
% Proteoform % Proteoform
Venom nerve growth factor P30894 D. russelii 2.11 1 2.13 1
Snake venom 5′-nucleotidase (5′NUC) 0.82 3 — —
Snake venom 5′-nucleotidase F8S0Z7 C. adamanteus 0.16 1 — —
5′-nucleotidase U3T7C6 O. okinavensis 0.17 2 — —
Snake venom 5′-nucleotidase CL3322.contig1_DrSL* D. russelii 0.49 3 — —
Cysteine-rich secretory protein (CRiSP) 0.95 1 — —
Cysteine-rich venom protein ablomin Q8JI40 G. blomhoffii 0.95 1 — —
Phosphodiesterase (PDE) 0.25 1 0.31 1
phosphodiesterase 1 CL3655.contig2_DrSL* D. russelii 0.25 1 0.31 1
Aminopeptidase 0.35 2 0.15 2
Xaa-Pro aminopeptidase 2 A0A0B8RNS9 B. irregularis 0.20 1 0.13 1
Xaa-Pro aminopeptidase 2-like Unigene32033_DrSL* D. russelii 0.15 2 0.02 2
Table 1. Proteomes of Daboia siamensis venoms from Guangxi and Taiwan profiled using nano-ESI-
LCMS/MS. * indicate venom protein identified based on tryptic peptides matched to sequence from in-
house transcripts database. Mass spectrometric data and peptide sequences are available in Supplementary 
Information Files S2A and B. D. russelii, Daboia russelii; D. siamensis, Daboia siamensis; M. lebetina, 
Macrovipera lebetina; N. naja, Naja naja; Vipera berus berus, V. berus berus; C. rhodostoma, Calloselasma 
rhodostoma; C. adamanteus, Crotalus adamanteus; O. okinavensis, Ovophis okinavensis; G. blomhoffii, Gloydius 
blomhoffii; B. irregularis, Boiga irregularis.
Antivenom
Protein concentration 
(mg/ml)
Daboia siamensis Monovalent Antivenom, Taiwan (DsMAV-Taiwan) 19.3 ± 0.5
Daboia siamensis Monovalent Antivenom, Thailand (DsMAV-Thai) 40.8 ± 0.3
Gloydius brevicaudus Monovalent Antivenom (GbMAV) 168.5 ± 0.7
Deinagkistrodon acutus Monovalent Antivenom (DaMAV) 181.1 ± 6.4
Table 2. Protein concentrations of the four antivenoms used.
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and diversity of venom proteins49–53. The major protein families (Kunitz-type serine protease inhibitor or KSPI, 
PLA2, snaclec, SVMP and SVSP) expressed in both Ds-Guangxi and Ds-Taiwan venoms were essentially the 
same, suggesting that these paralogous proteins from specimens of the two locales were highly conserved with 
evolutionary significance. The variations in the proteoforms probably implied further molecular adaptation to 
different ecological niches.
The predominance of KSPI in both Ds-Guangxi and Ds-Taiwan venoms is in agreement with the high abun-
dance of this non-enzymatic protein reported in the venom proteomes of the Russell’s viper from Pakistan 
(28.4%)12 and western India (32.5%)14. KSPI however was not reported in the venom proteome of the Myanmese 
D. siamensis37, although more recently this protein has been isolated from the Myanmese and Chinese D. siamensis 
venoms29,30. The KSPI proteoforms detected in the present study showed sequences matched to those reported 
previously for D. siamensis of Myanmar30, China29 and an unreported locale54. In general, KSPI are protease 
inhibitors with approximately 60–66 amino acids (~7 kDa) and are homologous to the conserved Kunitz motif 
present in the bovine pancreatic trypsin inhibitor55. Besides its serine protease inhibitory activity29,30 which could 
be important for venom protein storage in the venom glands, KSPI of Russell’s viper venom has also been shown 
to exhibit anticoagulant effect56,57. The pathophysiological role of KSPI in Ds-Guangxi and Ds-Taiwan venoms 
hence may be coagulopathy-related but the properties of the purified toxin await further investigation.
The high abundance of PLA2 in both D. siamensis venoms from Guangxi and Taiwan is in line with the find-
ing of high content of PLA2 (~35%) in the Myanmese D. siamensis venom31. PLA2 is a dominant venom protein 
family in virtually all reported D. russelii venom proteomes, including those from Pakistan (32.8–63.8%)12,13, 
Western India (32.5%)14 and Sri Lanka (35%)15. However, the activities of the different PLA2 subtypes are diverse, 
and the effects can be ranging from no toxicity to high lethality31,58,59. The PLA2 detected in Ds-Guangxi and 
Ds-Taiwan venoms were apparently of different subtypes, implying that the PLA2 toxic activities could be diverse. 
In Ds-Taiwan venom, the presence of PLA2 RV-4 and RV-7 (in a ratio of 1:1) is consistent with the PLA2 isolated 
from the Taiwanese Russell’s viper venom reported earlier, where the PLA2 formed a heterodimeric complex that 
induced presynaptic neurotoxicity60. Putative neurotoxic PLA2 were also detected in Ds-Guangxi venom (daboi-
atoxin A, B chain and DsM-b1)61,62. However, neurotoxicity is mainly reported in envenomation by D. russelii in 
Sri Lanka and some parts of southern India8,26,63,64; it is not a commonly observed clinical feature in envenom-
ation by the eastern Russell’s vipers in Southeast Asia26, Taiwan21 or China17,65. The neurotoxicity induced by D. 
siamensis PLA2 in laboratory animals probably reflects the complex interactions between toxins and the neurons 
of different specificity in animals60, where the natural prey such as rodents appear to be more susceptible to the 
PLA2-induced neurotoxicity than human beings are.
Figure 2. Immunological binding activity of antivenoms (DsMAV-Taiwan, DsMAV-Thai, DaMAV, GbMAV 
and a 1:1 mixture of DaMAV:GbMAV) toward the venom antigens of Daboia siamensis from Guangxi and 
Taiwan.
D. siamensis 
venom MCDa (µg/ml)
Challenge dose 
(2MCD) (µg/ml)
DsMAV-Taiwan GbMAV DaMAV
EDb (µl, mg/ml)
Normalized ED, 
n-EDc (mg/g) EDb (µl, mg/ml)
Normalized ED, 
n-EDc (mg/g) EDb (µl, mg/ml)
Normalized ED, 
n-EDc (mg/g)
Guangxi 0.23 ± 0.06 0.46 0.044 ± 0.002,2.03 ± 0.12 105.2
1.183 ± 0.017,
0.07 ± 0.00 0.4
>10,
<0.01 <0.05
Taiwan 0.15 ± 0.04 0.30 0.036 ± 0.003,1.41 ± 0.13 73.1
2.633 ± 0.088,
0.02 ± 0.00 0.1
>10,
<0.01 <0.05
Table 3. Procoagulant effect of Daboia siamensis venoms sourced from Guangxi and Taiwan and its 
neutralization by antivenoms. MCD: Minimal clotting dose; ED: Effective dose. aMinimal clotting dose was 
defined as the dose of venom (µg/ml) required to cause clotting in 5 minutes. bEffective dose was defined as the 
dose of antivenom capable of prolonging the clotting time of challenge dose to 3 times that of the control. ED 
was expressed in units of antivenom volume (µl) and venom amount per unit volume of antivenom (mg/ml). 
cNormalized ED was derived from ED (mg/ml) by normalizing the antivenom volume by antivenom protein 
concentration.
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D. siamensis-envenomed patients in China and Taiwan often developed coagulopathy and bleeding diathe-
sis with or without renal complication17–21. The hemotoxicity of D. siamensis venom is collectively caused by a 
number of toxins. Viperid PLA2, including a neutral PLA2 purified from D. russelii venom, were known to exhibit 
Figure 3. Efficacy of the Taiwan Daboia siamensis Monovalent Antivenom (DsMAV-Taiwan) in neutralizing 
the toxic effects of D. siamensis venoms from Guangxi and Taiwan. (A) Procoagulant effect; (B) Hemorrhagic 
effect. (C) Lethal effect.
D. siamensis 
venom
MHDa  
(µg/mouse)
Challenge dose 
(2MHD) (µg/mouse)
DsMAV-Taiwan GbMAV DaMAV
ED50b  
(µl, mg/ml)
Normalized ED50, 
n-ED50c (mg/g)
ED50b  
(µl, mg/ml)
Normalized ED50, 
n-ED50c (mg/g)
ED50b  
(µl, mg/ml)
Normalized ED50, 
n-ED50c (mg/g)
Guangxi 3.42 ± 0.12 6.84 0.871 ± 0.159,7.85 ± 3.70 406.74
>5,
<1 <6
>5,
<1 <6
Taiwan 8.21 ± 0.31 16.42 0.418 ± 0.082,39.28 ± 7.17 2035.35
>5,
<1 <6
>5,
<1 <6
Table 4. Hemorhagic effect of Daboia siamensis venoms sourced from Guangxi and Taiwan and its 
neutralization by antivenoms. MHD: Minimal hemorrhagic dose; ED50: Median effective dose. aMinimal 
hemorrhagic dose was defined as the amount of venom (µg) required to induce a skin hemorrhagic lesion 
of 10 mm diameter. bMedian effective dose was defined as the dose of antivenom capable of reducing the 
venom hemorrhagic activity of 2MHD by 50%. ED50 was expressed in units of antivenom volume (µl) and 
venom amount per unit volume of antivenom (mg/ml). cNormalized ED50 was derived from ED50 (mg/ml) by 
normalizing the antivenom volume by its protein concentration.
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anticoagulant activity66,67. Other venom proteins detected in substantial amounts in Ds-Guangxi and Ds-Taiwan 
venoms were mainly hemotoxins that can induce consumptive coagulopathy and hemorrhage, such as snaclec, 
SVSP and SVMP.
Snaclecs (comprising C-type lectins and C-type lectin-like proteins of snake venom) are non-enzymatic toxins 
that can modulate thrombosis and hemostasis68–70. Various proteoforms of snaclec were detected in both venom 
proteomes, including dabocetin, a heterodimer consisting alpha and beta subunits that inhibit ristocetin-induced 
platelet aggregation32. Two RVV-X light chains which are homologous to snaclecs were also detected in the ven-
oms. As part of the RVV-X metalloproteinase, these C-type lectin-like proteins were suggested to play a regula-
tory role in the calcium-dependant activation of factor X, probably through the recognition of specific sites of the 
zymogen factor X68,71.
Snake venom serine protease (SVSP) is another important protein family of viperid venoms that can cause 
venom-induced consumptive coagulopathy38,72,73. Several SVSP proteoforms were detected in the D. siamen-
sis venom proteomes, one of which is Factor V activating enzyme (RVV-V), a serine protease that specifi-
cally activates Factor V (through cleavage at Arg1545-Ser1546 bond) to induce prothrombinase complex in a 
calcium-dependent manner74. The presence of alpha and beta fibrinogenases in the venoms also suggests that 
fibrinogenolytic activity may contribute to systemic coagulopathy in envenomation. Besides, the SVMP VLAIP-A 
detected in the Ds-Guangxi and Ds-Taiwan venoms is another hemotoxin known to induce fibrinogenolysis and 
coagulopathy75. More importantly, the Factor X activating enzyme (RVV-X), present in both D. siamensis venoms, 
is a potent procoagulant enzyme unique to Russell’s viper. RVV-X is a heterotrimeric metalloproteinase (93 kDa) 
composed of a heavy chain (from PIII-SVMP containing metalloproteinase, disintegrin-like and cysteine rich 
domains, 58 kDa) and two light chains of snaclecs (beta-chain, ~19 kDa and gamma-chain, ~16 kDa)68,71,76. In this 
study, the higher abundance of RVV-X in the Ds-Taiwan venom corroborated the stronger procoagulant effect 
of the venom on human citrated plasma. On the other hand, the hemorrhagic PIII-SVMP daborhagin-K was 
detected only in Ds-Guangxi venom; this PIII-SVMP was similar to the potent hemorrhagin SVMP purified from 
the Myanmese D. siamensis venom34. The substantial amount of PIII-SVMP detected in the venom proteomes 
hence supported the clinical presentation of hemorrhages in D. siamensis envenomation. Nevertheless, the dis-
tinctive presence of daborhagin-K in Ds-Guangxi venom correlated with the more potent hemorrhagic effect of 
the venom (shown in this study), and this venom property might be associated with the prominent local and sys-
temic bleeding reported in Chinese D. siamensis envenoming20. Clinically, the potential renal complication (acute 
kidney injury) of Russell’s viper envenoming could be due to the nephrotoxic effect of SVMP and PLA2 mediated 
through cytotoxic activity or secondary to renal hypoperfusion in severe bleeding26,77,78.
In the current study, LAAO was detected only in Ds-Guangxi venom, consistent with the observation of a 
more intense protein band around 60 kDa on the SDS−PAGE under reducing conditions. The absence of LAAO 
in the proteome of Ds-Taiwan venom is puzzling as this enzyme is present in the venoms of most Viperidae and 
Elapidae11,79–81, including the Russell’s vipers of South Asia (Sri Lanka, India, Pakistan)12–16 and Myanmar37. In 
fact, the colors of the two venoms studied in the present study exhibited marked differences: the yellow coloration 
of Ds-Guangxi venom was likely due to the presence of flavin-containing LAAO, while the lyophilized Ds-Taiwan 
venom was white in color, implying the lack of this enzyme in the venom. The finding indicated that the amount 
of LAAO in Ds-Taiwan venom was low or negligible, a characteristic perhaps influenced by ecology and the 
condition of diet. LAAO may exhibit cytotoxicity and anti-microbial activity to facilitate prey digestion82, but its 
pathophysiological role in D. siamensis envenoming remains unclear.
The minor venom proteins (<10% of total venom proteins) i.e. snake venom vascular endothelial growth 
factor (svVEGF), nerve growth factor (svNGF), 5′nucleotidase (5′NUC), cysteine-rich secretory protein (CRiSP) 
and phosphodiesterase (PDE) may play a role in the predatory or digestive function of the venoms. Some of these 
venom components were known to induce hypotensive or proinflammatory effects, thereby facilitating the sub-
duing of prey. For instance, svVEGF has been shown to increase capillary permeability83 and induces hypotensive 
effect84. Meanwhile, svNGF through the release of nitric oxide and/or histamine, 5′NUC through the release of 
purines (adenosine) and PDE through the alteration of extracellular levels of adenosine and other purines85, may 
D. siamensis 
venom Challenge dose i.v. LD50 (µg/g)a ED50 (µl)b ER50 (mg/ml)c
Potency, P 
(mg/ml)d
AV protein 
concentration (mg/ml)
Normalized P, 
n-P (mg/g)e
DsMAV-Taiwan
Guangxi 5 0.18 (0.12–0.27) 11.24 1.76 (1.17–2.64) 1.41 19.3 ± 0.5 73.1
Taiwan 5 0.09 (0.06–0.14) 4.90 2.02 (1.35–3.14) 1.62 19.3 ± 0.5 83.9
GbMAV
Guangxi 5 0.18 (0.12–0.27) 91.24 0.22 (0.14–0.33) 0.17 168.5 ± 0.7 1.0
DaMAV
Guangxi 5 0.18 (0.12–0.27) N.E. N.E. N.E. 181.1 ± 6.4 N.E.
Table 5. Lethality of Daboia siamensis venoms sourced from Guangxi and Taiwan and the efficacy of 
antivenoms in neutralizing the lethal effect. LD50: Median lethal dose; ED50: Median effective dose; ER50: Median 
effective ratio; MCD: Minimal clotting dose; ED: Effective dose; N.E.: Non-effective. aMedian lethal dose was 
defined as the dose of venom (µg/ml) at which 50% of mice were dead. bMedian effective dose was defined as the 
dose of antivenom (µl) at which 50% of mice survived. cMedian effective ratio was defined as the ratio of venom 
(mg) to the volume dose of antivenom (ml) at which 50% of mice survived. dPotency, P was defined as the 
amount of venom (mg) completely neutralized by one ml of antivenom (ml). eNormalized P, n-P was defined as 
the neutralization potency of the antivenom in mg venom/g antivenom protein.
www.nature.com/scientificreports/
9SCienTiFiC REPORTS |  (2018) 8:8545  | DOI:10.1038/s41598-018-25955-y
contribute to the venom-induced hypotensive effect or venom spread in the prey. Furthermore, the release of 
adenosine may cause platelet aggregation inhibition, thereby worsening the hemostatic derangement in Russell’s 
viper envenomation85. Also, it has been shown that PDE could strongly inhibit ADP-induced platelet aggregation 
in human plasma, hence potentiating the hemotoxic effect of the venom86. On the other hand, CRiSP (detected 
in Ds-Guangxi venom) was similar to ablomin of Gloydius blomhoffii, a minor venom protein that targets L-type 
voltage-gated calcium channels (Cav) and blocks smooth muscle contraction87. The toxicological property of this 
protein in D. siamensis venom remains to be further studied.
In mainland China, there are two widely distributed medically important pit vipers namely D. acutus 
(five-pace snake, also known as sharp-nosed pit viper) and G. brevicaudus (short-tail pit viper/Chinese mamushi). 
Specific antivenoms effective against these two pit vipers have been developed for clinical treatment88–90. These 
antivenoms for pit vipers (DaMAV for D. acutus and GbMAV for G. brevicaudus) were anecdotally reported to 
have been used as alternative antidote to treat D. siamensis envenomation in mainland China in the absence of 
the specific D. siamensis antivenom. In this study, the weak immunoreactivity of DaMAV and GbMAV against 
the D. siamensis venoms indicated that the two heterologous antivenoms had very limited binding activity toward 
the venom antigens of D. siamensis. This is likely due to the substantial differences in the compositions and anti-
genicity of venom proteins between D. siamensis and the two Chinese pit vipers. For instance, the PLA2 subtypes 
reported from the venoms of G. brevicaudus and D. acutus have amino acid sequences varied from those of D. sia-
mensis in this study91,92. KSPI which formed the major component of D. siamensis venom have not been reported 
from the two pit viper venoms. Furthermore, the PIII-SVMP subtype was the main SVMP form expressed in 
both Ds-Guangxi and Ds-Taiwan venoms. However, in the Chinese G. brevicaudus venom, close to 65% of the 
total venom proteins were made up of a mixture of PII and PIII-SVMP91, while approximately only 10% of PI and 
PIII-SVMP was reported in the Taiwanese D. acutus venom93. The variability of protein families and proteoforms 
in these venoms imply that the toxins are likely diverse in their antigenicity. Compared with Ds-Taiwan venom, 
Ds-Guangxi venom was slightly less immunoreactive toward DsMAV-Taiwan, indicating that the antigenicity 
of some venom proteins varied between the two D. siamensis. On the other hand, the weak binding activity of 
DsMAV-Thai toward both Ds-Guangxi and Ds-Taiwan venom proteins implied that the Thai D. siamensis venom 
could be more diverse antigenically from the venoms of the geographically distant Ds-Guangxi and Ds-Taiwan.
The potent procoagulant and hemorrhagic effects of D. siamensis venoms correlated with the hemotoxic syn-
drome of D. siamensis envenomation in the region. In China, D. siamensis envenoming has been reported to 
cause severe bleeding including cerebral hemorrhage20; hence, it is essential to ensure that the antivenom used 
clinically is able to neutralize this hemorrhagic effect of the venom, besides neutralizing the procoagulant and 
lethal effects. The present study demonstrated that the heterologous DaMAV and GbMAV were rather ineffective 
in cross-neutralizing the hemotoxic (procoagulant and hemorrhagic) effects of Ds-Guangxi venom, even though 
GbMAV showed weak cross-neutralizing capability against the venom lethality when given at a very high dosage, 
judging from its low potency. The finding in this study therefore suggests that both DaMAV and GbMAV may not 
be the appropriate treatment of D. siamensis envenomation. On the other hand, Ds-Guangxi and Ds-Taiwan ven-
oms shared conserved antigenicity of key toxins, thus enabling DsMAV-Taiwan to neutralize the procoagulant, 
hemorrhagic and lethal effects of Ds-Guangxi venom effectively.
Conclusion
Shotgun proteomics showed that the principal toxins in the venoms of D. siamensis from Guangxi and Taiwan 
were comparable. The venom proteins within each protein family, however, varied between the two D. siamensis 
venoms. The subproteomic variation between the two could be reflective of ecological adaptation to diet since 
the mainland and the insular populations are physically long separated by the Taiwan Strait. However, the venom 
divergence could also be the result of random fixation of neutral alleles, with sequence differences that relate to 
neither dietary nor ecological factors on fitness. Both D. siamensis venoms exhibited potent hemotoxicity and 
lethality. Ds-Guangxi venom was comparatively more potent in hemorrhagic effect while Ds-Taiwan venom was 
a stronger procoagulant. Immunoreactivity and neutralization studies further revealed that the antigenicity of the 
major toxins of D. siamensis were relatively well conserved across the Strait. The study further showed that the 
heterologous DaMAV and GbMAV did not confer effective cross-neutralization against the venom hemotoxicity 
and lethality of Ds-Guangxi.
Materials and Methods
Chemicals and materials. All chemicals and reagents used in the study were of analytical grade. 
Ammonium bicarbonate, dithiothreitol (DTT) and iodoacetamide were purchased from Sigma-Aldrich (USA). 
Mass spectrometry sequencing grade of trypsin proteases, and HPLC grade solvents used in the studies were 
purchased from Thermo Scientific™ Pierce™ (USA). Millipore ZipTip® C18 Pipette Tips were purchased from 
Merck (USA).
Venoms and antivenoms. The venom of Daboia siamensis of the mainland of China was a pooled sample 
milked from several adult specimens (n > 10, average venom yield 30–59 mg) captured in Guangxi. The venom of 
D. siamensis from the insular Taiwan was a gift from Professor Inn-Ho Tsai from the National Taiwan University. 
The venoms were stored as lyophilized samples at −20 °C until use. Four different antivenoms were used in the 
present study: (a) Taiwanese D. siamensis Monovalent Snake Antivenom (DsMAV-Taiwan, neutralization efficacy 
not indicated in product sheet, lyophilized; batch no. FR10301; expiry date: Oct 31st, 2019, product of Taiwan 
Central for Disease Control in Taipei); (b) Thai D. siamensis Monovalent Snake Antivenom (DsMAV-Thai, 0.6 mg 
venom neutralized/ml of antivenom, lyophilized; batch no. WR00212; expiry date: Nov 19th, 2017, product of 
Queen Saovabha Memorial Institute in Bangkok). Both antivenoms (a) and (b) are purified F(ab)’2 obtained 
from sera of horses hyperimmunized against the venom of D. siamensis of the respective geographical origin. (c) 
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Gloydius brevicaudus (short-tailed mamushi) Monovalent Snake Antivenom (GbMAV, contains 6000 IU/vial of 
10 ml, lyophilized; batch no. 20141001; expiry date: Oct 30th, 2017); (d) Deinagkistrodon acutus (sharp-nosed pit 
viper) Monovalent Snake Antivenom (DaMAV, contains 2000 IU/vial of 10 ml, lyophilized; batch no. 20140501; 
expiry date: May 26th, 2017). Both (c) and (d) are products from Shanghai Serum Bio-Technology Co., Ltd.in 
Shanghai, and are purified F(ab)’2 obtained from sera of horses hyperimmunized against the venom of G. brevi-
caudus and D. acutus respectively. All antivenoms were used before expiry.
Animals. Albino mice (ICR strain, 20–30 g) were supplied by the Animal Experimental Unit (AEU), Faculty 
of Medicine, University of Malaya. The animals were handled according to the Council for International 
Organization of Medical Sciences (CIOMS) guideline on animal experimentation94. All methods were carried out 
in accordance with the guidelines and regulations approved by the Institutional Animal Care and Use Committee 
(IACUC) of University of Malaya (Protocol approval number: 2014-09-11/PHAR/R/TCH).
Estimation of antivenom protein concentration. Protein concentrations of antivenoms (DsMAV- 
Taiwan, DsMAV-Thai, GbMAV and DaMAV) were determined using Thermo Scientific™ Pierce™ BCA (bicin-
choninic acid) protein assay kit with bovine serum albumin as protein standard calibration. The protein concen-
trations were expressed as means ± S.E.M. of triplicates.
Whole venom in-solution tryptic digestion and protein identification by tandem mass spec-
trometry (nano-ESI-LCMS/MS). Whole venom in-solution tryptic digestion was carried out in three tech-
nical replicates for each of the venom. Twenty micrograms for each sample of D. siamensis venoms (Ds-Guangxi 
and Ds-Taiwan) were subjected to reduction with DTT, alkylation with iodoacetamide, and digested in-solution 
with mass-spectrometry grade trypsin proteases as described previously49. Briefly, the digested peptides eluates 
were reconstituted in 7 µl of 0.1% formic acid in water. Peptides separation were performed by 1260 Infinity 
Nanoflow LC system (Agilent, Santa Clara, CA, USA) connected to Accurate-Mass Q-TOF 6550 series with a 
nano electrospray ionization source. The eluate was subjected to HPLC Large-Capacity Chip Column Zorbax 
300-SB-C18 (160 nl enrichment column, 75 µm × 150 mm analytical column and 5 µm particles) (Agilent, Santa 
Clara, CA, USA). Injection volume was adjusted to 1 µl per sample, using a flow rate of 0.4 µl/min, with linear 
gradient of 5–70% of solvent B (0.1% formic acid in 100% acetonitrile). Drying gas flow was 11 L/min and dry-
ing gas temperature was 290 °C. Fragmentor voltage was 175 V and the capillary voltage was set to 1800 V. Mass 
spectra was acquired using Mass Hunter acquisition software (Agilent, Santa Clara, CA, USA) in a MS/MS mode 
with an MS scan range of 200–3000 m/z and MS/MS scan range of 50–3200 m/z. Data were extracted with MH+ 
mass range between 50 and 3200 Da and processed with Agilent Spectrum Mill MS Proteomics Workbench soft-
ware packages version B.04.00 against merged database incorporating both non-redundant NCBI databases of 
Serpentes (taxid: 8570) and in-house transcripts database. Carbamidomethylation was specified as a fixed mod-
ification and oxidized methionine as a variable modification. The identified proteins or peptides were validated 
with the following filters: protein score > 20, peptide score > 10 and scored peak intensity (SPI) >70%. Identified 
proteins were filtered to achieve False discovery rate (FDR) <1% for the peptide-spectrum matches. The proteins 
identified were classified as toxins or non-toxins according to their putative functions. The abundance of individ-
ual venom toxin was estimated based on its mean spectral intensity (MSI) relative to the total MSI of all proteins 
identified through the in-solution mass spectrometry49.
Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE). SDS-polyacrylamide 
gel electrophoresis (SDS-PAGE) was conducted according to method of Laemmli95 calibrated with the Thermo 
Scientific Spectra Multicolor Broad Range Protein Ladder (10–260 kDa). The venoms of both D. siamensis 
(Ds-Guangxi and Ds-Taiwan) was loaded onto a 15% gel and the electrophoresis was performed under reducing 
condition at 80 V for 2.5 h. Proteins were stained with Coomassie Brilliant Blue R-250 for gel visualization.
Immunological binding assay. Immunological binding activities between venom antigens and antiven-
oms were examined with an indirect enzyme-linked immunosorbent assay (ELISA). The immunoplate wells were 
precoated with 10 ng of venom antigens at 4 °C overnight. The plate was then flicked dry and rinsed four times 
with phosphate-buffered saline with 0.5% Tween®20 (PBST). Antivenoms were prepared at a protein concentra-
tion of 10 mg/ml each, and 100 µl appropriately diluted antivenom (1:3000) was added to each antigen-coated 
well, followed by incubation for 1 h at room temperature. After washing the plate four times with PBST, 100 µl of 
appropriately diluted horseradish peroxidase-conjugated antihorse-IgG (Jackson ImmunoResearch Inc., USA) 
in PBST (1:8000) was added to the well and incubated for another hour at room temperature. The excess com-
ponents were removed by washing four times with PBST. A hundred microliters of freshly prepared substrate 
solution (0.5 mg/mL o-phenylenediamine and 0.006% hydrogen peroxide in 0.1 M citrate-phosphate buffer, pH 
5.0) was added per well. The enzymatic reaction was allowed to take place in the dark for 30 min at room temper-
ature. The reaction was subsequently terminated by adding 50 µL of 12.5% sulphuric acid, and the absorbance at 
492 nm was read using Tecan Infinite M1000 Pro plate reader (Tecan Laboratories, Switzerland). Immunological 
binding activity was expressed as percentage of relative absorbance (highest binding activity set as 100%) between 
two comparing antivenoms in immunological binding toward the both D. siamensis venoms (Ds-Guangxi and 
Ds-Taiwan)96. Values were means of triplicates ± S.E.M., and the significance of difference was analyzed using 
unpaired t-test with p value <0.05.
Venom procoagulant activity and antivenom neutralization. Procoagulant effect of the venom 
was determined by adding 100 µl of citrated human plasma (containing 40 µl of 0.4 M CaCl2/ml) to 100 µl of 
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D. siamensis venoms of various concentrations in saline at 37 °C according to a modified turbidimetric 
method96,97. The absorbance at 405 nm was monitored every 30 s over 30 min. This produced a plot of absorbance 
versus time (min) with an initial lag time at which absorbance began to increase drastically due to cloudiness of 
clot formation, followed by a hyperbolic curve to a plateau. The clotting time was determined as the time when 
the absorbance became 0.02 U greater than the mean of the first two absorbance measurements. The minimal 
clotting dose (MCD) was defined as the dose of venom that induces coagulation in 5 min.
In neutralization study, venom concentration equivalent to 2 times minimal coagulation dose (2 MCD) was 
pre-incubated with various doses of the antivenoms (DsMAV-Taiwan, GbMAV and DaMAV) at 37 °C for 30 min 
before the addition of 100 µl citrated human plasma. The determination of clotting time in the neutralization 
assay was performed as described above. The effective dose (ED) was defined as the dose of antivenom that pro-
longed the clotting time of human plasma 3 times that of the control (2 MCD, without antivenom).
The effective dose (ED) was calculated using the following formulation:
(1)
Effective dose (ED, mg/ml) 2 times minimal coagulation dose (2 MCD, mg)
Dose of antivenom that prolonged the clotting time 3 times that of the control (ml)
=
For comparative purpose, ED values of antivenoms were normalized (n-ED) by their respective protein amount 
and expressed as milligram of venom neutralized per gram of antivenom protein (mg/g).
Hemorrhagic activity of D. siamensis venom and antivenom neutralization. Hemorrhagic effect 
was assessed by intradermal venom injection into the dorsal skin of ICR mice (20–25 g, n = 3) as described by 
Gutiérrez et al.98. The animals were euthanized with urethane 90 min after venom exposure and the skins were 
removed. Minimal hemorrhagic dose (MHD) was defined as the amount of venom that induces a skin hem-
orrhagic lesion of 10 mm diameter. For neutralization assays, various doses of antivenom (DsMAV-Taiwan, 
GbMAV and DaMAV) were pre-incubated with a constant amount of venom challenge dose (2MHD) at 37 °C for 
30 min prior to intradermal injection into the animals. The neutralization of hemorrhagic effects was expressed 
as median effective dose (ED50), defined as the amount of reconstituted antivenom in µl or the ratio of mg venom/
ml reconstituted antivenom in which the venom activity was reduced by 50%.
The median effective dose (ED50) was calculated using the following formulation:
=
Median effective dose (ED , mg/ml)
2 times minimal hemorhagic dose (2 MHD, mg)
Dose of antivenom in which the venom activity was reduced by 50% (ml) (2)
50
For comparative purpose, ED50 values of antivenoms were normalized (n-ED50) by their respective protein 
amount and expressed as milligram of venom neutralized per gram of antivenom protein (mg/g).
Determination of venom lethality and neutralization by antivenom. Median lethal doses (LD50) of 
venoms were determined by intravenous injection (via caudal veins) into ICR mice (n = 4 per dose, 20–25 g). The 
survival ratio was recorded after 48 h. In antivenom neutralization assay, pre-incubation of venom and antivenom 
was conducted as described by Tan et al.11. A challenge dose at 5 times LD50 of the venom dissolved in nor-
mal saline was pre-incubated with various dilutions of antivenoms (DsMAV-Taiwan, GbMAV and DaMAV) at 
37 °C for 30 min and the mixture was injected intravenously into the mice (n = 4 per dose, 20–25 g). The mice 
were allowed free access to food and water ad libitum, and the ratio of survival was recorded at 48 h post injec-
tion. Neutralizing capacity was expressed as ED50, defined as the amount of reconstituted antivenom that gives 
50% survival in the venom-challenged animals. These parameters were calculated according to the Probit anal-
ysis method99 using BioStat 2009 analysis software (AnalystSoft Inc., Canada). Neutralization capacity was also 
expressed in term of ‘neutralization potency’ (P, defined as the amount of venom in milligram neutralized com-
pletely by a unit volume of antivenom in millilitre, mg/ml)96,100. The neutralization potency (P) is a more direct 
indicator of antivenom neutralizing capacity, and is theoretically unaffected by the number of LD50 in the chal-
lenge dose. For comparative purpose, P values of antivenoms were normalized (n-P) by their respective protein 
amount and expressed as milligram of venom neutralized per gram of antivenom protein (mg/g).
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